California-based pharmaceutical company Cytori Therapeutics has entered into definitive agreements to raise $10 million, before placement agent fees and offering expenses.

At closing, Cytori will issue and sell to select investors 4,771,174 units, with each unit consisting of one share of the company’s common stock and 1.4 warrants, at a purchase price of $2.10 per unit.

The warrants, which will represent the right to acquire up to an additional 6,679,644 shares of common stock, will be exercisable beginning six months after the closing of the transaction at an exercise price of $2.59 per share, which was the company’s consolidated closing bid price per share on March 9, 2009, and will expire five years after the date the warrants are first exercisable.

Cytori is offering the securities in this transaction pursuant to an effective shelf registration statement. Piper Jaffray & Co. is serving as the sole placement agent. The transaction is expected to close on or about March 13, 2009, subject to the satisfaction of customary closing conditions.